Resistance acquired to third generation tyrosine kinase inhibitors in non small cell lung cancer

Authors

  • Thanya Runciman Gozzer Unidad de Tumores Torácicos, Clínica Aliada, Lima, Perú
  • Carlos Carracedo Gonzáles Unidad de Tumores Torácicos, Clínica Aliada, Lima, Perú

DOI:

https://doi.org/10.15381/anales.v79i4.15639

Keywords:

Drug Resistance, Tyrosine, Lung Neoplasms

Abstract

Resistance to third-generation tyrosine kinase inhibitors (TKI) is an increasingly frequent event in clinical practice; however, the exact mechanisms by which tumor cells develop such resistance allowing their survival are unknown. A case of resistance to osimertinib (AZD9291) in non small cell lung cancer, evidenced by next generation sequencing (NGS) and its possible therapeutic approach is described.

Downloads

Published

2018-12-30

Issue

Vol. 79 No. 4 (2018)

Section

Reporte de Casos

License

Copyright (c) 2018 Anales de la Facultad de Medicina

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Those authors who have publications with this magazine accept the following terms:

  1. Authors will retain their copyrights and guarantee the journal the right of first publication of their work, which will be simultaneously subject to Creative Commons Attribution License that allows third parties to share the work as long as its author and its first publication this magazine are indicated.
  2. Authors may adopt other non-exclusive licensing agreements for the distribution of the version of the published work (eg, deposit it in an institutional electronic file or publish it in a monographic volume) provided that the initial publication in this magazine is indicated.
  3. Authors are allowed and recommended to disseminate their work over the Internet (eg: in institutional telematic archives or on their website) before and during the submission process, which It can produce interesting exchanges and increase quotes from the published work. (See El efecto del acceso abierto ).

How to Cite

1.
Runciman Gozzer T, Carracedo Gonzáles C. Resistance acquired to third generation tyrosine kinase inhibitors in non small cell lung cancer. An Fac med [Internet]. 2018 Dec. 30 [cited 2024 Jul. 17];79(4):327-30. Available from: https://revistasinvestigacion.unmsm.edu.pe/index.php/anales/article/view/15639